全文获取类型
收费全文 | 583篇 |
免费 | 40篇 |
专业分类
耳鼻咽喉 | 7篇 |
儿科学 | 87篇 |
妇产科学 | 3篇 |
基础医学 | 30篇 |
临床医学 | 28篇 |
内科学 | 258篇 |
皮肤病学 | 60篇 |
神经病学 | 11篇 |
特种医学 | 4篇 |
外科学 | 83篇 |
预防医学 | 14篇 |
药学 | 2篇 |
肿瘤学 | 36篇 |
出版年
2023年 | 2篇 |
2021年 | 2篇 |
2020年 | 11篇 |
2019年 | 6篇 |
2018年 | 16篇 |
2017年 | 13篇 |
2016年 | 23篇 |
2015年 | 21篇 |
2014年 | 31篇 |
2013年 | 25篇 |
2012年 | 59篇 |
2011年 | 71篇 |
2010年 | 19篇 |
2009年 | 10篇 |
2008年 | 35篇 |
2007年 | 42篇 |
2006年 | 52篇 |
2005年 | 36篇 |
2004年 | 34篇 |
2003年 | 24篇 |
2002年 | 22篇 |
2001年 | 29篇 |
2000年 | 18篇 |
1999年 | 11篇 |
1997年 | 1篇 |
1995年 | 2篇 |
1992年 | 5篇 |
1991年 | 2篇 |
1990年 | 1篇 |
排序方式: 共有623条查询结果,搜索用时 828 毫秒
1.
J Douglas Rizzo John R Wingard Andre Tichelli Stephanie J Lee Maria Teresa Van Lint Linda J Burns Stella M Davies James L M Ferrara Gérard Socié 《Biology of blood and marrow transplantation》2006,12(2):138-151
More than 40000 hematopoietic cell transplants (HCTs) are performed worldwide each year. With improvements in transplant technology, larger numbers of transplant recipients survive free of the disease for which they were transplanted. However, there are late complications that can cause substantial morbidity. Many survivors are no longer under the care of transplant centers, and many community health care providers may be unfamiliar with health matters relevant to HCT. The Center for International Blood and Marrow Transplant Research (CIBMTR), European Group for Blood and Marrow Transplantation (EBMT), and American Society for Bone Marrow Transplantation (ASBMT) have developed these recommendations to offer care providers suggested screening and prevention practices for autologous and allogeneic HCT survivors. 相似文献
2.
3.
4.
5.
6.
7.
Marina Díaz-Beyá Myriam Labopin Johan Maertens Mahmoud Alijurf Jakob Passweg Beelen Dietrich Harry Schouten Gerard Socié Nicolaas Schaap Rainer Schwerdtfeger Liisa Volin Mauricette Michallet Emmanuelle Polge Jorge Sierra Mohamad Mohty Jordi Esteve Arnon Nagler the Acute Leukaemia Working Party of the European Society for Blood Marrow Transplantation 《British journal of haematology》2020,189(5):920-925
Acute myeloid leukaemia (AML) with t(6;9)(p23;q34) is a poor-risk entity, commonly associated with FLT3-ITD (internal tandem duplication). Allogeneic stem-cell tranplantation (allo-SCT) is recommended, although studies analysing the outcome of allo-SCT in this setting are lacking. We selected 195 patients with t(6;9) AML, who received a first allo-SCT between 2000 and 2016 from the EBMT (European Society for Blood and Marrow Transplantation) registry. Disease status at time of allo-SCT was the strongest independent prognostic factor, with a two-year leukaemia-free survival and relapse incidence of 57% and 19% in patients in CR1 (first complete remission), 34% and 33% in CR2 (second complete remission), and 24% and 49% in patients not in remission, respectively (P < 0·001). This study, which represents the largest one available in t(6;9) AML, supports the recommendation to submit these patients to allo-SCT in CR1. 相似文献
8.
9.
10.
Marie Robin Kavita Raj Sylvie Chevret Jordan Gauthier Hugues de Lavallade David Michonneau Donal McLornan Régis Peffault de Latour Victoria Potter Austin Kulasekararaj Flore Sicre de Fontbrune Antonio Pagliuca Ibrahim Yakoub‐Agha Gérard Socié Ghulam J. Mufti 《European journal of haematology》2018,101(4):466-474